姓名：任秀宝

职称：教授、主任医师

一、教育经历 

1.1984.9-1989.7天津第二医学院 临床医学 医学学士

2.1993.9-1996.7白求恩医科大学 内科学 医学硕士

3.2003.9-2006.7 天津医科大学 肿瘤学 医学博士

4.2006-2007  美国Vanderbilt大学肿瘤中心FELLOW

二、工作经历 

1.1989.9-1993.6天津第二医学院，助教

2.1996.7-2000.12天津医科大学肿瘤医院，主治医师

3.2000.12-2005.12天津医科大学肿瘤医院，副主任医师

4.2005.12-今  天津医科大学肿瘤医院，科主任

三、研究方向（包括承担课题项目）

1. 国家自然科学基金联合基金重点支持项目：基于高通量肿瘤抗原多肽筛查的常见实体瘤的个体化全疗程精准免疫治疗策略研究，260万，2021-2024，主持，在研

2. 国家自然科学基金：FABP4+C1q+巨噬细胞通过重塑脂肪酸代谢诱导AMPK去磷酸化增强JAK2/STAT3正反馈通路的抗肺癌机制，46万，2024-2027，主持，在研 

3. 国家重点研发计划：靶向恶性实体肿瘤免疫细胞治疗新技术的研发及其临床转化路径的规范化建立，486万，2018-2020，子课题负责人，结题 

4. 国家自然科学基金：乳腺癌MDSCs通过CyclinD-CDK4/6-pRb轴调控PD-1-PD-L1+B细胞免疫抑制功能的研究，57万，2019-2022，主持，结题 

5. 国家自然科学基金：乳腺癌髓源性抑制细胞(MDSC)对B细胞功能的影响及调控机制，80万，2015-2018，主持，结题

6. 国家自然科学基金：CUL4A在小细胞肺癌发生发展中的作用及其调控机制，70万，2013-2016，主持，结题 

7. 国家973计划：基于纳米技术的肺癌早期检测研究，364万，2012-2015，子课题负责人，结题

8. 国家863计划：抗体产业化关键原材料研发及生产平台的建立，137万，2012-2015，子课题负责人，结题

四、学术兼职 

1. 中华医学会天津分会肿瘤专业委员会主任委员（2017至今）

2. 中国医药生物技术协会医药生物技术临床应用专业委员会副主任委员（2008至今）

3. 中国抗癌协会肿瘤生物治疗专业委员会副主任委员（2017至今）

4. 中国研究型医院学会生物治疗学专业委员会副主任委员（2015至今）

5. 中国医药生物技术协会常务理事（2008至今）

6. 天津市抗癌协会理事（2015至今）

五、近五年发表的学术论文

1. Liu S, Sun Q, Ren X*. Novel strategies for cancer immunotherapy: counter-immunoediting therapy. Journal of Hematology & Oncology, 2023 Apr 13;16(1):38

2. Li L, Xing T, Chen Y, Xu W, Fan B, Ju G, Zhao J, Lin L, Yan C, Liang J, Ren X*. In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-γ-induced ferroptosis of hepatocellular carcinoma. Cell Death Discov. 2023 Sep 4;9(1):331.

3. Luo J, Pang S, Hui Z, Zhao H, Xu S, Yu W, Yang L, Sun Q, Hao X, Wei F, Wang J, Ren X*. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4+ T cells through regulating type 2 conventional dendritic cells. Theranostics. 2023 Sep 4;13(14):4836-4857.

4. Hui Z, Ren Y, Zhang D, Chen Y, Yu W, Cao J, Liu L, Wang T, Xiao S, Zheng L, Pu Y, Wei F, You J, Ren X*. PD-1 blockade potentiates neoadjuvant chemotherapy in non-small cell lung cancer via increasing CD127+ and KLRG1+ CD8 T cells. NPJ Precision Oncology, 2023 May 25;7(1):48.

5. Wang Z, Shi X, Zhao Y, Zhou J, Zhang S, Wang J, Yu W, Zhang X, Ren X*, Zhao H. DC101, an anti-VEGFR2 agent, promotes high-endothelial venule formation and immune infiltration versus SAR131675 and fruquintinib. Biochem Biophys Res Commun. 2023 Jun 18;661:10-20.

6. Li R, Zhang D, Ren B, Cao S, Zhou L, Xiong Y, Sun Q, Ren X*. Therapeutic effect of haploidentical peripheral blood stem cell treatment on relapsed/refractory ovarian cancer. Bull Cancer. 2023 Mar;110(3):285-292.

7. Liu S, Meng Y, Liu L, Lv Y, Wei F, Yu W, Wang L, Zhang X, Ren X*, Sun Q*.Rational pemetrexed combined with CIK therapy plus anti-PD-1 mAbs administration sequence will effectively promote the efficacy of CIK therapy in non-small cell lung cancer. Cancer Gene Ther. 2023 Feb;30(2):277-287.

8. Hui Z, Zhang J, Ren Y, Li X, Yan C, Yu W, Wang T, Xiao S, Chen Y, Zhang R, Wei F, You J, Ren X*. Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC). Cell Death Dis. 2022 Jul 13;13(7):607.

9. Liu S, Meng Y, Liu L, Lv Y, Yu W, Liu T, Wang L, Mu D, Zhou Q, Liu M, Ren Y, Zhang D, Li B, Sun Q, Ren X*. CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer. Cell Death & Disease, 2022 May 6;13(5):441.

10. Zhou L, Xiong Y, Wang Y, Meng Y, Zhang W, Shen M, Zhang X, Li S, Ren B, Li R, Han Y, Zhang J, Cao S, Du W, Sun Q, Wei F, An X, Yang L, Zhang Y, Ma W, Xu W, Zhang Y, Jiang J, Xu X, Xia J, Liu L, Ren X*. A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2022 Jul 21:S1525-7304(22)00153-X.

11. Zhao H, Wang H, Zhao Y, Sun Q, Ren X*. Tumor-Resident T Cells, Associated With Tertiary Lymphoid Structure Maturity, Improve Survival in Patients With Stage III Lung Adenocarcinoma. Front Immunol. 2022 May 19;13:877689

12. Xu H, Feng H, Zhang W, Wei F, Zhou L, Liu L, Zhao Y, Lv Y, Shi X, Zhang J, Ren X*. Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence. Exp Cell Res. 2022 Jul 1;416(1):113157.

13. Zhu S, Zhang C, Sun Q, Wang Y, Yu W, Wei F, Ren X*.Trained Immunity of IL-12-, IL-15-, and IL-18-Induced CD3+CD56+ NKT-Like Cells. J Oncol. 2022 Jun 23;2022:8724933.

14. Wang J, Zhou J, Zhou Q, Qi Y, Zhang P, Yan C, Ren X*. Dysregulated Th1 cells in lung squamous cell carcinoma. J Leukoc Biol. 2022 Jun 10.

15. Yan C, Chang J, Song X, Qi Y, Ji Z, Liu T, Yu W, Wei F, Yang L*, Ren X*. Lung cancer-associated mesenchymal stem cells promote tumor metastasis and tumorigenesis by induction of epithelial-mesenchymal transition and stem-like reprogram. Aging (Albany NY). 2021 Mar 19;13(7):9780-9800.

16. Zhang W, Meng Y, Yang L, Shen M, Zhou L, Li R, Wang Y, Du W, Xiong Y, Han Y, Zhang X, Liu L,  Ren X*. Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events.  Cancer Biol Med. 2021 Aug 11;18(4):1109-17.

17. Zhang C, Yin J, Zheng J, Xiao J, Hu J, Su Y, Zhou K, Zhang Y, Zhang X, Zhang H, Sun Q, Wang Y, Yu W, Wei F, Zhao Q, Li L,  Ren X*. EZH2 identifies the precursors of human natural killer cells with trained immunity. Cancer Biol Med. 2021 Sep 24;18(4):1021-39.

18. Wang J, Yang F, Sun Q, Zeng Z, Liu M, Yu W, Zhang P, Yu J, Yang L, Zhang X, Ren X, Wei F. The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma. Cancer Biol Med. 2021 Aug 30;18(4):1134-47.

19. Liu M, Wei F, Wang J, Yu W, Shen M, Liu T, Zhang D, Wang Y, Ren X, Sun Q *. Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1(-)PD-L1(+) Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer. Cell Death Dis. 2021. 12(5): 465.

20. Wang K, Wang J,  Liu T, Yu W, Dong N, Zhang C, Xia W, Wei F, Yang L,  Ren X*. Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer.Cancer Biol Med. 2021 Feb 15;18(1):155-171.

21. Liu M, Zhang L, Zhou Q, Wang Y, Sun Q*, Ren X*. The Distinct Impact of TAM Infiltration on the Prognosis of Patients With Cardia and Non-Cardia Gastric Cancer and Its Association With H. pylori Infection. Front Oncol. 2021 Dec 3;11:737061.

22. Hui Z, Zhang J, Zheng Y, Yang L, Yu W, An Y, Wei F, Ren X. Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and in vitro Expanded iTregs. Front Immunol. 2021 Mar 31;12:619932.

23. Zeng Z, Yan B, Chen Y, Zhang L, Zhu J, Yang F, Wei F, Ren X*. Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study. Transl Lung Cancer Res. 2020. 9(6): 2401-2410.

24. Chen Y, Zhang L, Yan B, Zeng Z, Hui Z, Zhang R, Ren X*, You J*. Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer. Transl Lung Cancer Res. 2020 Jun;9(3):761-767.

25. Liu L, Gao Q, Jiang J, Zhang J, Song X, Cui J, Ye Y, Wang Z, Zhang X, Ren X. Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357. Signal Transduct Target Ther. 2020 Oct 19;5(1):244.

26. Zeng Z, Yang F, Wang Y, Zhao H, Wei F, Zhang P, Zhang X, Ren X. Significantly different Immunoscores in lung adenocarcinoma and squamous cell carcinoma and a proposal for a new immune staging system. Oncoimmunology, 2020 Oct 7;9(1):1828538

27. Li B, Zhang B, Wang X, Zeng Z, Huang Z, Zhang L, Wei F, Ren X, Yang L. Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis. Oncoimmunology. 2020 Aug 28;9(1):1807291.

28. Hui Z, Wei F, Ren H, Xu W, Ren X. Primary tumor standardized uptake value (SUVmax) measured on 18F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer.  J Cancer Res Clin Oncol. 2020 Oct;146(10):2595-2605

29. Han Y, Mu D, Liu T, Zhang H, Zhang J, Li S, Wang R, Du W, Hui Z, Zhang X, Ren X. Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study. Thorac Cancer. 2020 Nov 4. doi: 10.1111/1759-7714.13731

30. Wei L, Wu N, Wei F, Li F, Zhang Y, Liu J, Ren X. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer. Int Immunopharmacol. 2020 Jul;84:106506

31. Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, Wei F, You J, Xu W, Ren X*. New Insight on the Correlation of Metabolic Status on 18 F-FDG PET/CT With Immune Marker Expression in Patients With Non-Small Cell Lung Cancer. Eur J Nucl Med Mol Imaging. 2020 May;47(5):1127-1136.

32. Sun Q, Zhang X, Wang L, Gao X, Xiong Y, Liu L, Wei F, Yang L, Ren X*. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human. Cell Death Dis. 2019 Jun 17;10(7):475.

33. Guo C, Zhao H, Wang Y, Bai S, Yang Z, Wei F, Ren X*. Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma. Front Oncol, 2019 May 28;9:439.

34. Ren X*. Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle. Cancer Biol Med. 2019 May;16(2):205-210.

35. Wang K, Zheng Y, Yang Y, Wang J, Li B, Wei F, Zhao H, Ren X. Nociceptin Receptor Is Overexpressed in Non-small Cell Lung Cancer and Predicts Poor Prognosis. Front Oncol. 2019 Apr 5;9:235.

36. Yan C, Chang J, Song X, Yan F, Yu W, An Y, Wei F, Yang L, Ren X*. Memory stem T cells generated by Wnt signaling from blood of human renal clear cell carcinoma patients. Cancer Biol Med. 2019 Feb;16(1):109-124.

37. Zhao H, Dong N, Liu T, Zhang P, Zheng Y, Yang L, Ren X*. Clinical Significance of Serum Type III Interferons in Patients With Gastric Cancer. J Interferon Cytokine Res. 2019 Mar;39(3):155-163.

38. Sun Q, Li S, Wang Y, Peng H, Zhang X, Zheng Y, Li X, Li L, Chen R, Chen X, Bai W, Jiang X, Liu L, Wei F, Wang B, Zhang Y, Li H,  Ren X*, Zhang H*. Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis. Cell Death and Differentiation, 2018 Jun;25(6):1160-1173

39. Shen M#, Wang J#, Yu W, Zhang C, Liu M, Wang K, Yang L, Wei F, Wang E*, Sun Q*, Ren X*. A novel MDSC-induced PD-1-PD-L1+ B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties. OncoImmunology, 2018 Feb 20;7(4):e1413520.

六、荣誉和奖励 

1. 天津市肿瘤医院“杰出学者”（2017年）

2. 国家人事部“新世纪百千万人才”（2009年）

3. “国家特支计划”百千万工程领军人才（2012年）

4. 天津市“131创新型人才”

5. 天津市“十五”立功先进个人

6. 天津市“五一劳动奖章”（2010年）

七、联系方式 

1.通讯地址：天津市河西区体院北环湖西路 

2.电话：23340123 

3. E-mail：renxiubao@tjmuch.com